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Abstract 
Objective—To determine the progression rates to 
AIDS in women in Dublin. 
Subjects and methods—109 HIV-1 sero-positive 
women who presented to the Department of 
Genitourinary Medicine, St. James’s Hospital, 
Dublin, were included in a retrospective analysis. Of 
these 101 (93%) were intravenous drug users 
(IVDUs), 7 were heterosexual partners of IVDUs and 
one had a hetero-sexual partner of no known risk 
group. Forty-four women (40%) had had 57 children 
since the time of their first known HIV seropositive 
test. Progression rates from CDC Stage 11/111 co 
AIDS are computed. Progression curves are 
generated according to the Kaplan-Meier method 
using the Statistical Analysis Software (SAS). 
Results—The estimated cumulative progression rate 
at 5 years was 24% (SE 6.6%). 17 out of 109 (15.6%) 
developed AIDS. The mean follow up lime was 2.8 
years (SE 0.2). The prevalence of oesophageal 
candidiasis taking development of AIDS as the point 
in time was 9 out of 17 (53%), of Mycobacterium 
hominis infection (TB) 5 (29%) and of Pneunmcystis 
carcinii pneumonia (PCP) 2 (12%). There was no 
statistical difference in progression rates to AIDS 
between those women who had children after 
becoming infected versus those who had none. 
Conclusions—Progression rates to AIDS in Irish 
women is higher than reported in other studies of 
homosexual/bisexual men, but is similar to rates 
estimated for both male and female IVDUs. 
Oesophageal candidiasis is the commonest 
presenting AIDS diagnosis followed by TB, while 
PCP is rare, contrary to the findings of similar 
studies in the USA. 
(Genitourin Med 1994;70:81-83) 
Introduction 
The acquired immunodeficiency syndrome (AIDS) 
epidemic has grown slowly in Ireland. The first 
reported case was in a homosexual man in 1982 
and there were a total of 258 cases in the Republic 
by the end of 1991.1 However, by November 1991, 
1146 individuals in Ireland had tested positive for 
die HIV antibody, 150 (13.1%) of whom 
were female. Most of these women are intravenous drug 
users (IVDU). The proportion of AIDS cases arising 
from the IVDU risk group has risen steadily from 30% 
at the end of 1987 to 37% at die end of 1991 and with it 
the proportion of AIDS cases among women. A similar 
increase in die incidence of AIDS in women has been 
reported in other countries, in particular the USA.2-3 
Therefore it is of increasing importance to examine the 
natural history of HIV infection in women. Here we 
outline the details of such a study. The majority of Irish 
HIV cases are centred in the Dublin area and 109 HIV 
positive Irish women have attended the Genito urinary 
clinic in St. James’s Hospital, Dublin. A retrospective 
analysis of HIV positive female admissions to the clinic 
for the period January 1987 to January 1991 was 
conducted. 
 Progression rates to any Center for Disease 
Control (CDC) group IV disease and to AIDS for these 
women are presented. Possible effect of pregnancy 
during the course of HIV infection on progression rates 
is explored. Progression rates for women who do not 
have babies during the course of their HIV infection are 
compared with those for women who do. We also 
compare our progression rates with those of homosexual 
cohort studies and with other cohort studies of IVDU’s 
compiled from the literature. 
Patients and methods 
A total of 109 women who presented at the Dublin 
sexually transmitted disease clinic between January 
1987 and January 1990 were anu-HIV-1 seropositive. 
They were followed to 1 February 1991. The dates of 
their first positive HIV test ranged from 15 January, 
1983 to 30 September, 1990, the median date being 15 
June, 1987. The CDC classification of 19874 for the 
manifestation of HIV infection was used to classify 
patients. The major transmission category was TV drug 
usage. Of the 109 women, 101 (93%) were IV drug 
users, seven were heterosexual partners of IV drug users 
(6.4%) and one had a heterosexual partner of no known 
risk group. Six of the 101 IV drug users were 
prostitutes. At the time of study, 74 of the 101 (73%) 
were ex IVDUs of whom 54 (53%) were on methadone, 
Twenty-seven were current users (27%), 16 of whom 
were on methadone. Seventeen patients received anti-
retroviral therapy, 14 after an AIDS diagnosis. CD4 ceil 
counts were not available on a routine basis so PCP 
prophylaxis was 
not initiated unless die patient had reached CDC Stage 
IV diagnosis. 
 Forty-four (40%) of the women had had 
children, since the time of their first known HIV 
positive test. A total of 57 children were born; nine 
women had two children, two had three and the 
remaining 33 had a single pregnancy since 
seroconversion. 
 Progression races from CDC stages II and III to 
AIDS were computed. All progression curves were 
generated according to the Kaplan-Meier method using 
the Statistical Analysis Software (SAS). For each 
patient the date of first known HIV-seropositive result 
was the starting point on the follow-up scale. The 
exception to this were seven patients for whom an HIV-
seronegative date was available. For these seven, the 
starting point was taken as the date midway between the 
last known negative and first known positive tests for 
anti-HIV. In computing progression rates to AIDS ail 
109 patients were included in the risk set. The number 
of days of follow-up was taken to the date at which the 
patient developed an AIDS illness or the date of last 
visit 
Table 1 Distribution of first AIDS-defining events 
 Number 
Oesophageal candidiasis 6 
Mycobacteria hominis infection 5 
PCP 1 
Specific neurological disease 0 
Other (CDC 4C1) 2 
Oesophageal candidiasis and PCP 1 
Oesophageal candidiasis and TB 1 
Oesophageal candidiasis and other 1 
 17 
Table 2 Cumulative progression rates (standard 
errors) to CDC stage 4 and to AIDS from date of entry 






1 85 5.7 (2.3) 
2 64 8.4 (2.9) 
3 51 11.6 (3.6) 
4 38 11.6 (3.6) 
5 12 24.0 (6.6) 
6 5 36.7 (12.8) 
Number of subjects who progressed: 17 out of 109 
(15.6%). Mean follow-up time: 2.8 years (SE 0.2). 
at the clinic at which the patient was asymtomatic, 
before 1 February 1991. 
Results 
The average age at entry to the Study was 25.6 years 
with a standard error of 0.5 years. The ages ranged from 
19 to 41. At study entry, 100 of die women were in 
CDC stage II and 7 were in stage III. Two presented 
with AIDS. Twenty-one of the 109 (19.3%) progressed 
to some stage IV disease of whom six had CDC stage 
IV C2 (ARC) as their first diagnosis and 13 had an 
AIDS diagnosis. Of the six who did not have AIDS as 
the first diagnosis, two subsequently went on to develop 
AIDS. This gave a total of 17 of 109 (15.6%) who 
developed AIDS in this group of women. In all of these 
cases opportunistic infection was the first CDC stage IV 
presentation (table 1). If the development of AIDS is 
taken as the point in time then the prevalence for 
oesophageal candidiasis is 53%, for TB is 35% and for 
PCP is 12%, The incidence of opportunistic infections 
changed over time. For oesophageal candidiasis there 
was one in 1987, one in 1988, two in 1989 and seven in 
1990. 
 The progression rates to AIDS and the associated 
standard errors, together with the sample sizes on which 
the estimates are based are shown in table 2. The 
progression rate to AIDS at 4 years is 12% and at 5 
years is 24% (fig 1). 
 All the women were of child-bearing age and 44 
(40%) of them had children after becoming infected. 
Eight (18%) of women who had babies progressed to 
AIDS and the rate was 14% for women who did not 
have babies. The Kaplan-Meier progression curves to 
AIDS for the two groups were nor significantly 
different. Likewise there was no statistical difference in 
progression between current IVDUs and ex-IVDUs 
(Log Rank Test). Moreover, age was not a statistically 
confounding factor in either of these analyses. 
Discussion 
The pattern of AIDS presentation as seen in table 1 is 
different from that reported in the USA, where the 
incidence of PCP among infected women is higher and 
the incidence of oesophageal candidiasis is rare. Guinan 
et al5 in a study of 1819 women with AIDS in the USA 
reported a 66% incidence of PCP, similar to males in 
the USA. In a study at The New York Hospital6 of 
women with AIDS, 57.1% had PCP as their first 
opportunistic infection versus 10.7% with oesophageal 
candidiasis. By contrast 35.3% had oesophageal 
candidiasis in this study. However Carpenter et al7 in a 
study of 200 anti-HIV positive women in Rhode Island 
reported a similar figure of 34% with oesophageal 
candidiasis as an AIDS defining event. This may reflect 
local disease variations associated with different risk 
groups or environmental factors. Carpenter et al have 
also noted that clinical signs of advanced HIV-related 
immune deficiency vary around 
Table 3 Cumulative progression rates (%) to 
AIDSX in studies of IVDU’s. 
 Year: 1 2 3 4 5 6 
Alcabes et 
al9: USA (n = 
343) 
 5.6 11.6 17.6 22.8 29.1 
Jordi et al10: 
Spain (n = 
649) 
  11.0 18.0 48.0  
Montalla et 
al11: Italy (n 
= 539) 





9.0  26.0    
the world, the reasons for which are not fully 
understood. 
 Kelly et al (1990)8 compiled progression rates to 
AIDS of six independent cohorts of homosexual and 
bisexual men. In each study the dace of seroconversion 
of the subjects was either known or estimated. The 
estimated cumulative rates at five years ranged from 11 
% to 23% with a median of 14%. The corresponding 
estimate in this study is 24% (SE 6.6%), the highest in 
comparison. There are two possible explanations for 
this. Some women may have been HIV positive for a 
long time before coming to the clinic. The study at The 
New York Hospital also found that women tend Co seek 
treatment late in their clinical course. Thus they have 
been infected for longer than their follow-up in this 
study, and as it is well known chat the risk of AIDS for 
HIV infected persons increases over time, it is possible 
we have overestimated the progression rates. An 
alternative explanation is that most of the women are 
IVDUs and progression rates among IVDUs are higher 
than in other risk groups because of an already 
weakened immune system. Table 3 shows cumulative 
progression rates from four studies of IVDU’s,9-12 male 
and female, compiled from the literature. The estimated 
cumulative races at five years ranged from 23% to 48% 
with a median of 35%. The corresponding estimate in 
this study is 24% showing good agreement. 
Undoubtedly, progression rates for IVDUs seem to be 
consistently higher than in die homosexual/bisexual 
group, suggesting that IVDUs have a poorer prognosis. 
Currently there is no evidence to suggest mat 
progression races differ between male and female 
IVDUs. There is, however, a lot of variability across 
studies perhaps because of unknown seroconversion 
dates. 
 Selwyn et al13 found no adverse effect of 
pregnancy or HIV progression in a prospective study of 
24 seropositive IVDUs. Our data also support this study. 
This contrasts with earlier studies of HIV, in which HIV 
disease was found to progress dramatically during or 
following pregnancy. Lindgren et al14 suggest that 
progression was related to the delivery of an affected 
baby. Comprehensive data on the HIV status of the 
children born in our study is incomplete and therefore 
we cannot comment on this issue at this time. 
 An increase in AIDS among women from 
heterosexual partners is a good marker for future trends 
in the heterosexual population, 
and is of particular concern. However, the extent to 
which HIV transmission occurs from the IVDU 
population to the general heterosexual population is not 
known. Six percent of women in this study were 
infected in this manner. Nine percent of AIDS cases in 
Ireland to December 1991 had occurred in heterosexuals 
and heterosexuals with no known risk accounted for 
11% of HIV seropositive cases. Two studies, in the 
USA15 and Italy16 have compared progression rates for 
women in the IVDU and heterosexual risk groups. The 
US study concluded that women in the IVDU risk group 
progress more rapidly than women without IVDU 
history, while the Italian study found the reverse was 
true, Owing to the small numbers of heterosexuals in 
this study, it was not possible to compare these groups. 
Further studies to clarify this important issue are 
urgently required. 
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